Are Screening Tests Reliable to Rule Out Direct Oral Anticoagulant Plasma Levels at Various Thresholds (30, 50, or 100 ng/mL) in Emergency Situations?

Chest

Volumn 153, Issue 1, 2018, Pages 288-290

  Jabet, Arnaud ^a   Stepanian, Alain ^a,b   Golmard, Jean Louis ^c   Flaujac, Claire ^d   Joly, Bérangère S ^a,b   Gouin Thibault, Isabelle ^d   Siguret, Virginie ^a,e  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Institut Cochin   (France)

^e Fondation Carpentier   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

BLOOD CLOTTING TEST; DRUG BLOOD LEVEL; EMERGENCY; HUMAN; LETTER; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTHROMBIN TIME; SCREENING TEST; THROMBIN TIME; UNIVERSITY HOSPITAL; BLOOD; CLINICAL TRIAL; EMERGENCY TREATMENT; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROCEDURES; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DABIGATRAN; EMERGENCY TREATMENT; HUMANS; PARTIAL THROMBOPLASTIN TIME; PYRAZOLES; PYRIDONES; REFERENCE VALUES; RIVAROXABAN; SENSITIVITY AND SPECIFICITY; THROMBIN TIME;

EID: 85040170058     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.09.047     Document Type: Letter

References (2)

1. Adcock, D.M., Gosselin, R.C., The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue. Int J Lab Hematol 39:suppl 1 (2017), 37–40.
2. Samuelson, B.T., Cuker, A., Siegal, D.M., et al. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants (DOACs): a systematic review. Chest 151:1 (2017), 127–138.